Brand-agnostic fitting companies, like True Spec Golf, will work with your budget and your needs as a player to find you something that will help you play your best golf. Not ready to invest in a ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

10x Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research report issued to clients and investors on Friday,Benzinga reports.

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full ...

TXG opened at $12.31 on Thursday. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -8.05 and a beta of 1.85. 10x Genomics has a 1 year low of $10.80 and a 1 year high of ...

10x Genomics Inc (NASDAQ:TXG) launched major new products across all three platforms, receiving a tremendous customer response. The company introduced new products in the single-cell portfolio ...

Thank you for standing by. My name is [Prilla] and I will be your conference operator today. At this time, I would like to welcome everyone to the 10x Genomics Fourth Quarter and Full Year 2024 ...

10x Genomics (TXG) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.41 per share a year ago. These figures are ...

Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for real-time ...